Vanguard Group Inc. grew its stake in shares of Chemed Corp. (NYSE:CHE) by 1.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,830,711 shares of the company’s stock after purchasing an additional 34,938 shares during the quarter. Vanguard Group Inc. owned approximately 11.45% of Chemed Corp. worth $374,435,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in CHE. Acrospire Investment Management LLC acquired a new stake in Chemed Corp. during the second quarter worth approximately $120,000. Pacad Investment Ltd. raised its holdings in Chemed Corp. by 250.0% during the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after purchasing an additional 500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Chemed Corp. by 12.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after purchasing an additional 83 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Chemed Corp. during the second quarter worth approximately $209,000. Finally, World Asset Management Inc acquired a new stake in Chemed Corp. during the second quarter worth approximately $216,000. 96.96% of the stock is currently owned by institutional investors.

A number of analysts have weighed in on CHE shares. BidaskClub cut shares of Chemed Corp. from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 22nd. Zacks Investment Research raised shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $213.00 target price on the stock in a report on Wednesday, August 23rd. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $209.00 target price on shares of Chemed Corp. in a report on Friday, September 1st. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $215.00.

In other Chemed Corp. news, Director Patrick P. Grace sold 500 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total value of $100,740.00. Following the sale, the director now directly owns 4,515 shares of the company’s stock, valued at $909,682.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin J. Mcnamara sold 15,000 shares of the stock in a transaction on Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the sale, the insider now directly owns 173,801 shares in the company, valued at $34,961,809.16. The disclosure for this sale can be found here. Insiders sold 16,500 shares of company stock worth $3,315,600 over the last ninety days. 5.32% of the stock is owned by corporate insiders.

Chemed Corp. (NYSE CHE) opened at 203.52 on Friday. The company has a 50-day moving average of $194.81 and a 200-day moving average of $197.29. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of 50.49 and a beta of 1.13. Chemed Corp. has a 52-week low of $132.92 and a 52-week high of $216.01.

Chemed Corp. (NYSE:CHE) last issued its earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The firm had revenue of $415.06 million for the quarter, compared to analyst estimates of $407.56 million. During the same period last year, the company earned $1.80 earnings per share. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities research analysts expect that Chemed Corp. will post $8.21 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Chemed Corp. (CHE) Shares Bought by Vanguard Group Inc.” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/chemed-corp-che-shares-bought-by-vanguard-group-inc/1614779.html.

Chemed Corp. Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Institutional Ownership by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.